These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23228943)

  • 21. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings.
    Urtishak KA; Robinson BW; Rappaport EF; Sarezky MD; Biegel JA; Nichols KE; Wilmoth DM; Wang LS; Stern JW; Felix CA
    Pediatr Blood Cancer; 2016 Jul; 63(7):1175-80. PubMed ID: 26999444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
    Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
    Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
    Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
    Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
    Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.
    Ahlmann M; Meyer C; Marschalek R; Burkhardt B; Koehler G; Klapper W; Juergens H; Rossig C
    Eur J Haematol; 2014 Oct; 93(4):349-53. PubMed ID: 24635731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pediatric B lineage leukemia with coincident MYC and MLL translocations.
    Meeker ND; Cherry AM; Bangs CD; Frazer JK
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):158-60. PubMed ID: 20829716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell.
    Chen MB; Shen WX; Yang Y; Wu XY; Gu JH; Lu PH
    J Cell Physiol; 2011 Jul; 226(7):1915-25. PubMed ID: 21506122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C.
    Vucicevic L; Misirkic M; Janjetovic K; Harhaji-Trajkovic L; Prica M; Stevanovic D; Isenovic E; Sudar E; Sumarac-Dumanovic M; Micic D; Trajkovic V
    Biochem Pharmacol; 2009 Jun; 77(11):1684-93. PubMed ID: 19428322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MLL duplication in a pediatric patient with B-cell lymphoblastic lymphoma.
    Mater DV; Goodman BK; Wang E; Gaca AM; Wechsler DS
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):e120-3. PubMed ID: 22052166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
    Brown P; Levis M; McIntyre E; Griesemer M; Small D
    Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
    Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
    Benito JM; Godfrey L; Kojima K; Hogdal L; Wunderlich M; Geng H; Marzo I; Harutyunyan KG; Golfman L; North P; Kerry J; Ballabio E; Chonghaile TN; Gonzalo O; Qiu Y; Jeremias I; Debose L; O'Brien E; Ma H; Zhou P; Jacamo R; Park E; Coombes KR; Zhang N; Thomas DA; O'Brien S; Kantarjian HM; Leverson JD; Kornblau SM; Andreeff M; Müschen M; Zweidler-McKay PA; Mulloy JC; Letai A; Milne TA; Konopleva M
    Cell Rep; 2015 Dec; 13(12):2715-27. PubMed ID: 26711339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
    Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
    Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in
    Wölfl M; Rasche M; Eyrich M; Schmid R; Reinhardt D; Schlegel PG
    Blood Adv; 2018 Jun; 2(12):1382-1385. PubMed ID: 29898879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1.
    Jang JH; Lee TJ; Yang ES; Min do S; Kim YH; Kim SH; Choi YH; Park JW; Choi KS; Kwon TK
    Exp Cell Res; 2010 Aug; 316(13):2194-203. PubMed ID: 20451517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway.
    Shin SM; Cho IJ; Kim SG
    Mol Pharmacol; 2009 Oct; 76(4):884-95. PubMed ID: 19620254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.